Failure of the anti-inflammatory parasitic worm product ES-62 to provide protection in mouse models of type I diabetes, multiple sclerosis, and inflammatory bowel disease by Doonan, James et al.
Doonan, James and Thomas, David and Wong, Michelle H. and Ramage, 
Hazel J. and Al-Riyami, Lamyaa and Lumb, Felicity E. and Bell, Kara S. 
and Fairlie-Clarke, Karen J. and Suckling, Colin J. and Michelsen, 
Kathrin S. and Jiang, Hui-Rong and Cooke, Anne and Harnett, Margaret 
M. and Harnett, William (2018) Failure of the anti-inflammatory parasitic 
worm product ES-62 to provide protection in mouse models of type I 
diabetes, multiple sclerosis, and inflammatory bowel disease. Molecules, 
23 (10). ISSN 1420-3049 , http://dx.doi.org/10.3390/molecules23102669
This version is available at https://strathprints.strath.ac.uk/65881/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
molecules
Article
Failure of the Anti-Inflammatory Parasitic Worm
Product ES-62 to Provide Protection in Mouse Models
of Type I Diabetes, Multiple Sclerosis,
and Inflammatory Bowel Disease
James Doonan 1, David Thomas 2, Michelle H. Wong 3, Hazel J. Ramage 1, Lamyaa Al-Riyami 1,
Felicity E. Lumb 1, Kara S. Bell 1, Karen J. Fairlie-Clarke 1, Colin J. Suckling 4,
Kathrin S. Michelsen 3, Hui-Rong Jiang 1 , Anne Cooke 2 , Margaret M. Harnett 5
and William Harnett 1,*
1 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK;
james.doonan@strath.ac.uk (J.D.); hazeljramage@gmail.com (H.J.R.); lamyaa.alriyami@gmail.com (L.A.-R.);
felicity.lumb@strath.ac.uk (F.E.L.); karabell@hotmail.co.uk (K.S.B.); karenfairlieclarke@gmail.com (K.J.F.-C.);
huirong.jiang@strath.ac.uk (H.-R.J.)
2 Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK; tdct2@cam.ac.uk (D.T.);
ac416@cam.ac.uk (A.C.)
3 F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute,
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA;
Michelle.Wong@cshs.org (M.H.W.); Kathrin.Michelsen@cshs.org (K.S.M.)
4 Department of Pure & Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, UK;
c.j.suckling@strath.ac.uk
5 Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences,
University of Glasgow, Glasgow G12 8TA, UK; margaret.harnett@glasgow.ac.uk
* Correspondence: w.harnett@strath.ac.uk
Received: 11 July 2018; Accepted: 10 October 2018; Published: 17 October 2018


Abstract: Parasitic helminths and their isolated secreted products show promise as novel treatments
for allergic and autoimmune conditions in humans. Foremost amongst the secreted products is
ES-62, a glycoprotein derived from Acanthocheilonema viteae, a filarial nematode parasite of gerbils,
which is anti-inflammatory by virtue of covalently-attached phosphorylcholine (PC) moieties. ES-62
has been found to protect against disease in mouse models of rheumatoid arthritis, systemic
lupus erythematosus, and airway hyper-responsiveness. Furthermore, novel PC-based synthetic
small molecule analogues (SMAs) of ES-62 have recently been demonstrated to show similar
anti-inflammatory properties to the parent molecule. In spite of these successes, we now show
that ES-62 and its SMAs are unable to provide protection in mouse models of certain autoimmune
conditions where other helminth species or their secreted products can prevent disease development,
namely type I diabetes, multiple sclerosis and inflammatory bowel disease. We speculate on the
reasons underlying ES-62’s failures in these conditions and how the negative data generated may
help us to further understand ES-62’s mechanism of action.
Keywords: ES-62; helminth; inflammatory bowel disease; multiple sclerosis; nematode; type 1 diabetes
1. Introduction
The success of parasitic helminths in evading detection and expulsion from their hosts is believed
to be due to a range of strategies that the parasites employ to regulate host immune responses and to
maintain homeostasis. Thus, active helminth infection and also immunomodulatory helminth-derived
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excretory/secretory (ES) products have been shown to induce a range of regulatory immune responses
that can skew host immunity (reviewed in [1]). Furthermore, such responses appear to have knock-on
effects, as epidemiological studies have shown that exposure early in life to helminth infections is
negatively correlated with the development of allergy and autoimmunity, and that anthelminthic
therapies can result in loss of helminth-induced immunoregulation (reviewed in [1]).
Amongst the most widely characterised helminth ES product is ES-62, which is produced
by Acanthocheilonema viteae (reviewed in [2]). ES-62 is a tetrameric protein that is decorated with
phosphorylcholine (PC) moieties covalently attached to N-type glycans. The PC is largely responsible
for ES-62’s immunomodulatory actions which, via degradation of MyD88 and downstream transducers
like PKC-α, can dampen inflammatory responses to pathogen-associated molecular patterns (PAMPS)
such as lipopolysaccharide (LPS), as well as to certain antigens (reviewed in [2]). Such subversion
of immune signalling dictates that ES-62 can be used to treat disease, both prophylactically and
therapeutically, in a number of pre-clinical models of autoimmunity and allergy, including rheumatoid
arthritis (RA; collagen-induced arthritis (CIA) (reviewed in [2])), systemic lupus erythematosus (SLE;
MRL/Lpr mouse model [3]), and asthma (acute and chronic ovalbumin (OVA)-induced asthma
models [4,5]). This has raised the idea of employing ES-62 as a novel therapy, but such thoughts are
tempered by its likely immunogenicity and by the fact that its active moiety is a post-translational
modification. Therefore, a library of synthetic non-immmunogenic, small molecule analogues (SMAs),
based around the structure of the active PC-moiety, was designed and screened to find compounds
mimicking ES-62’s immunomodulatory properties [6]. From this work, SMAs 11a and 12b were
identified as possessing anti-inflammatory profiles matching ES-62’s properties, both in vitro and
in pre-clinical models of RA, SLE and allergy [6–12]. However as parasitic helminths and their
ES products have been shown to be protective in a wide range of mouse models of inflammatory
conditions (reviewed in [13]), we decided to investigate the therapeutic potential of ES-62 and its SMAs
in other pathologies. In particular, we employed the non-obese diabetic (NOD) mouse model of type 1
diabetes (T1D), the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis
(MS), and the dextran sodium sulphate (DSS)-induced and T cell transfer models of inflammatory
bowel disease (IBD) in an attempt to gauge the range of ES-62’s therapeutic potential.
The NOD mouse spontaneously develops a Th1 response to islet antigens that results in
inflammatory infiltration of pancreatic islets from 4–5 weeks of age, leading to β cell destruction,
insulitis, and diabetes. There are a number of reports of parasitic worms, their extracts and products
preventing diabetes development in NOD mice. Thus, short term treatment of the mice from four
weeks of age with non-viable eggs or soluble extracts from the egg or worm of the parasitic trematode
Schistosoma mansoniwas found to be sufficient to prevent the development of diabetes and preserve
β islet cells [14]. Roles for NKT cells [14] and regulatory T cells (Tregs) [15] have been put forward
to explain these data. More recently, ES products from another trematode, Fasciola hepatica, were also
reported to prevent the onset of diabetes, specifically by inducing M2 peritoneal macrophages that
are capable of generating a potent Treg response [16]. With respect to nematodes, protection against
T1D was demonstrated using live Litomosoides sigmodontis larvae or adult worms and also adult worm
antigen (LsAg), acting via the generation of a Th2 immunological phenotype and the induction of
a Treg response [17]. Together, these data suggest that pathogenic Th1 responses can be subverted
by helminth-induced Th2 polarisation and immunoregulatory responses, to prevent diabetes in the
NOD mouse.
In MS models, unlike in the NODmouse where disease develops spontaneously, EAE is generated
following immunisation with myelin oligodendrocyte glycoprotein (MOG) or myelin basic protein
(MBP) in Complete Freunds Adjuvant (CFA) to induce a potent Th1/17 autoimmune response.
This model is characterised by infiltration of the central nervous system (CNS) by inflammatory T
cells and macrophages, which leads to rapid paralysis. Administration of S. mansoni eggs, S. japonicum
soluble egg antigen (SEA) or live F. hepatica infection was each found to suppress EAE by inducing
strong Th2 and Treg responses in the CNS that promoted IL-4 and reduced IFN-γ production [18–20].
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Furthermore, live infection with the model gastrointestinal nematode Heligmosomoides polygyrus
resulted in remission of active EAE disease [21] and transfer of regulatory B cells from the mesenteric
lymph nodes of such infected mice could prevent disease onset in recipient mice [22].
Inflammatory bowel disease (IBD) is an umbrella term for a collection of diseases, including
ulcerative colitis and Crohn’s disease that can be investigated using a variety of in vivo pre-clinical
models, in which helminth infections or the use of their ES products have proven to be effective in
reducing disease. For example, mirroring its effects in diabetes and EAE, S. mansoni SEA induced
potent Th2 and Treg responses that protected animals from generating an exaggerated immune
responses towards DSS-induced colitis [23]. Using this same DSS model, ES products from the
hookworm Ancylostoma caninum protected against colitis by dampening Th1/17 responses, again via
the promotion of Th2 immune responses [24].
Despite the different aetiologies/target organs involved in these autoimmune diseases, there are
similar underlying mechanisms; each disease being driven by a potent Th1/17 response that results
in the pathological destruction of tissue. Here, we demonstrate that despite our previous success in
exploiting the ability of ES-62 and the SMAs to dampen such responses, we were unable to (i) decrease
diabetes incidence in the NOD mouse model, (ii) prevent the onset of paralysis in the EAE model,
and (iii) protect against colonic inflammation in chronic IBD models. In spite of this, by reflecting on
the successes and failures of ES-62, we hope to further elucidate the immunoregulatory mechanisms of
action of this helminth product.
2. Materials and Methods
2.1. ES-62 and SMAs
Highly purified ES-62 was prepared from spent culture medium of adult mixed-sex A. viteae by size
exclusion centrifugation using endotoxin-free reagents and procedures, as described previously [25]: SMAs
were synthesised as previously described [6].
2.2. Type I Diabetes Model
The NOD mouse was employed as a model of type I diabetes (T1D), and initial experiments
were based on regimens where ES-62 had been successfully employed to prevent the development of
autoimmunity [3], and where extracts of adult Schistosoma mansoni, or its eggs, had been in effective in
preventing diabetes development [14]. BDC2.5 mice are T cell receptor transgenic mice expressing a
T cell receptor for islet antigen on CD4+ T cells [26]. The study was carried out in accordance with
the recommendations of the Animals (Scientific Procedures) act and was conducted under UK Home
Office project license regulations (numbers PPL 80/1560 and PPL 80/2242) after approval by the
Ethical Review Committees of the University of Cambridge. NOD mice and BDC2.5 NOD transgenic
mice were bred and maintained under specific pathogen-free barrier conditions. Mice were housed in
individually ventilated cages with standard ad libitum conditions.
Female NOD mice received intraperitoneal injections of 2 µg ES-62 in sterile PBS (n = 10 mice) or
sterile PBS alone (n = 13 mice) once a week from four weeks until 12 weeks of age. Non-diabetic female
NODmice (9–10-week-old, n = 9 mice/group) were injected six times intraperitoneally with sterile PBS
(Control) or 10 µg of ES-62 in sterile PBS over a two-week period. For the SMA experiment, 5-week-old
female NOD mice (n = 10 mice/group) received intraperitoneal injections of 1 µg of SMA 11a or
12b twice a week for 10 weeks. The incidence of diabetes was determined by monitoring glycosuria
using Diastix reagent strips (Bayer Diagnostics, Basingstoke, UK) and confirmed by a blood glucose
measurement of >13.3 mM, using a Breeze2 blood glucose meter (Bayer).
Bone marrow-derived dendritic cells (DCs) were generated by culturing bone marrow cells
flushed from NOD femurs and tibia, red cell lysed, re-suspended and cultured at 106/mL in Iscove’s
Modified Dulbecco’s Medium (IMDM) supplemented with 10% foetal calf serum (FCS), penicillin
(100 U/mL), streptomycin (100 µg/mL), 2-mercaptoethanol (25 µM), and L-glutamine (2 mM) in
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the presence of 20 ng/mL recombinant murine granulocyte-macrophage colony-stimulating factor
(GM-CSF; Preprotech, London, UK) and 10 ng/mL IL-4 (Preprotech, London, UK). Non-adherent cells
were discarded at day 3 and cells re-suspended in the supplemented medium described above for
a further 5–7 days before the non-adherent cells were used as DCs. DCs were washed and adjusted
to 5 × 104 cells/well in a flat bottomed, 96-well plate in 200 µL final volume. The cells were set
up in triplicate cultures and incubated with 500 ng/mL LPS (S. minnesota, Sigma, Poole, UK) PBS
and/or ES-62. The supernatants were collected at 48 or 72 h and analysed for cytokines by sandwich
enzyme-linked immunosorbent assay (ELISA).
Four-week-old BDC2.5NOD mice were given two injections of 2 µg ES-62 (in PBS with PBS as
a control) over the course of a week either by the intraperitoneal or subcutaneous route. Single cell
suspensions of red blood cell lysed spleen cells were cultured in the presence of BDC2.5 peptide in
the presence or absence of 1 or 2 µg ES-62. Supernatants were taken at 72 h and the presence of
cytokines in supernatants was assessed by ELISA. The BDC2.5 peptide (RTRPLWVRME) was supplied
by Cambridge Peptides, Cambridge, UK.
Analysis of cytokines produced by DCs or spleen cells was carried out using ELISA kits (R&D
systems, Abingdon, UK) for TNF-α IL-12p40, IL-6, IL-10, IL-4, and IFN-γ. Protocols were followed
according to the manufacturer’s instructions.
Single-cell suspensions were made from spleens of BDC2.5NODmice incubated with ES-62 as
described above for flow cytometry. Cells were washed and re-suspended in staining buffer (PBS
containing 2% bovine serum albumin and 0.05% NaN3). Fc receptors were blocked using antibody
24G2 (a kind gift from Dr Nick Holmes, University of Cambridge, Cambridge, UK). Cells were stained
with the following monoclonal antibodies directly conjugated to fluorochromes: anti-CD19-FITC,
anti-CD4-PE, anti-CD4-PerCP, and anti-CD25-PE (BD Pharmingen, Wokingham, UK), and then washed
and analysed using a FACScan flow cytometer and CELLQUEST software (Becton Dickinson Europe,
Erembodegem, Belgium).
2.3. Experimental Autoimmune Encephalomyelitis
EAE was employed as a model of MS using naïve C57BL/6 mice that were bred and maintained
in the Biological Procedure Unit at the University of Strathclyde. Mixed-sex animals (we find no effect
of gender on disease incidence or severity) at 7–9-weeks old were used in the experiments, which were
performed under the guidelines of the UK Animals (Scientific Procedures) Act 1986.
Mice were immunised subcutaneously on day 0 with 50 µL of 150 µg MOG35–55 peptide
(ChinaPeptides Co. Ltd., Shanghai, China) emulsified in 50 µL of CFA (Sigma) supplemented with
400 µgMycobacterium tuberculosis (BD Biosciences). In addition, each mouse received two injections
of pertussis toxin (PTX; Tocris Bioscience, Bristol, UK) intraperitoneally (150 ng in 100 µL PBS) on
day 0 and day 2. Mice received three doses of treatment with PBS (Control), 2 µg of ES-62, or 1 µg of
SMAs 11a or 12b on Day-2, Day 0, and Day 2 by the sub-cutaneous route. EAE clinical symptoms were
carefully monitored, and the clinical score was recorded based on the following evaluation system: 0:
normal with no clinical sign; 1: complete loss of tail tone; 2: hind limb weakness; 3: hind limb paralysis;
4: forelimb involvement in addition to hind limb paralysis; 5: moribund.
2.4. Induction and Assessment of Chronic Colitis
DSS-induced chronic colitis was initiated bymulti-cycle administration of DSS drinking water [27].
Female mice of eight weeks of age received 2.3% (w/v) DSS (40,000–50,000 MW; MP Biomedicals,
Irvine, CA, USA) in drinking water on days 1–5, 8–12, 15–19, and 22–26. Mice were injected with
PBS, ES-62 (2 µg/mouse), SMA 11a or SMA 12b (1 µg/mouse each) three times per week starting on
day 1 of DSS treatment. Mice were checked daily for the development of colitis by monitoring body
weight, gross rectal bleeding, and stool consistency, and were sacrificed at day 29. The cecum and
colon were removed, tissues were fixed in 10% formalin in PBS, paraffin-embedded, and cross sections
were stained with haematoxylin and eosin (H&E). Lamina propria mononuclear cells (LPMC) were
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isolated from the large intestine as previously described [28]. Single-cell suspensions of LPMC were
stained with anti-CD4 antibodies for flow cytometry. To determine the percentage of cells expressing
surface markers and the intensity of expression, samples were examined using a CyAn™ ADP flow
cytometer (Dako Cytomation, Carpinteria, CA, USA) and analysed with the FlowJo (TreeStar, Ashland,
OR, USA). Percentages of CD4+ cells were analysed on the gated lymphocyte population.
2.5. T Cell Transfer Model
Female C57BL/6 mice were used for donors, and male Rag1−/− mice of the C57BL/6 background
were used as recipients. Spleens were homogenised and the resulting cell suspension was passed
through a 25-gauge needle. CD4+ T cells were negatively selected using the EasySep Mouse CD4+ T
Cell Enrichment Kit (STEMCELL Technologies Inc., Vancouver, BC, Canada). Cells were labeled with
anti-CD4, anti-CD25, and anti-CD45RB. Using the MoFlow cell sorter (Dako Cytomation, Carpinteria,
CA, USA), CD4+ CD25− CD45RBhigh cells were purified by gating and sorting 40% of the highest
fluorescing CD45RB cells. Each recipient mouse was injected i.p. with 0.5 × 106 cells in sterile PBS.
Mice were injected with PBS, 11a, or 12b (1 µg/mouse each) three times per week, starting on day 1 of T
cell transfers. Animals were weighed and observed for signs of colitis over a 6- to 8-week period. Mice
were sacrificed at the indicated time points. Large intestines, and caeca were collected, formalin-fixed,
paraffin-embedded, and stained with H&E.
3. Results
3.1. Type I Diabetes
The NOD mouse spontaneously develops T1D, providing an animal model of the human
autoimmune disease. Previous studies have shown that helminth infections or helminth-derived
products are able to prevent the onset of diabetes in this mouse model (e.g., [14]). We therefore
examined the ability of ES-62 (Figure 1A,B) or its SMAs (Figure 1C,D) to inhibit diabetes. We generally
used time points that had shown efficacy in the previous helminth studies, and employed doses of
ES-62/SMAs that were effective in other models, although the data generated in Figure 1B rely on
a strategy that has been shown to be effective for Salmonella-mediated inhibition of NOD diabetes
onset [29]. It can be seen that in contrast to the earlier studies neither ES-62 nor SMAs 11a and 12b
were able to inhibit diabetes onset or to reduce incidence of disease.
We also examined the effects of ES-62 on cytokine production by NOD bone marrow derived-DCs
(DCs) in vitro, in the presence or absence of LPS. We included LPS in these cultures, as our previous
studies had shown that this revealed a cytokine-biasing effect of helminth molecules [14]. There was no
significant effect of ES-62 in vitro on cytokine production by NOD DCs (Figure 2). We also employed
BDC2.5 mice: these are T cell receptor transgenic mice expressing a T cell receptor for islet antigen on
CD4+ T cells [26]. We found that the administration of ES-62 to BDC2.5 transgenic mice in vivo had no
effect on spleen B and CD4+ T cell populations (Figure 3), nor on cytokine production by islet reactive
spleen cells (Figure 4).
Molecules 2018, 23, 2669 6 of 14
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ƺ ƺȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
Ȭ ȱ Ȭ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ƺȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱΐ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭȱ ȱ Ȭ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ
ȱ Ȭ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ
ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ
ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ Ȭ Ȭ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱΐ ȱ ȱ
Ȭ ȱ ȱ ȱ ȱ ȱ ȱΐ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱΐ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱΐ ȱ ȱ Ȭ ȱ ȱ ȱ
Figure 1. ES-62 and SMAs 11a and 12b do not protect against the development of type 1 diabetes.
(A) Four-week-old female non-obese diabetic (NOD) mice were injected subcutaneously with 2 µg of
ES-62 (n = 10) in 200 µL of sterile PBS once a week between four and 12 weeks of age. Control mice
(n = 13) were injected with 200 µL of sterile PBS according to the same protocol. (B) 9–10 week-old
female NOD mice were injected six times subcutaneously with sterile PBS (control) or 10 µg of ES-62 in
sterile PBS over a two-week period (n = 9). Five-week-old female NOD mice received intraperitoneal
injections of PBS (control) or 1 µg SMA 11a (C) or 12b (D) twice a week for 10 weeks (n = 10).
The incidence of diabetes was monitored by regularly checking for the presence of glycosuria.
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Figure 2. Effects of ES-62 on in vitro cytokine secretion by dendritic cells (DCs). DCs were prepared
from bone marrow as described in the Materials and Methods. On day 10, they were harvested and
incubated with medium alone, 500 ng/mL of LPS, 2 µg of ES-62 or with both 500 ng/mL of LPS and
2 µg of ES-62. At 72 h, supernatants were harvested and assayed for the presence of (A) IL-12p40,
(B) TNF-α, (C) IL-10, and (D) IL-6. Data points correspond to the mean plus SEM of each set of samples.
Molecules 2018, 23, 2669 7 of 14
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ Ȭ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱΐ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ
ȱ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱΐ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ΐ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ
Ȭ΅ ȱ ȱ Ȭ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ
Figure 3. Effects of sub-cutaneous or intra-peritoneal treatment with ES-62 on composition of BDC2.5NOD
splenocyte populations. Four-week-old BDC2.5NODmice were given two injections of 2 µg ES-62 over
the course of a week. After one week, splenocytes were harvested, and the percentage of B cells, CD4+
cells, and CD4+CD25+ cells was assessed by staining with (A) anti-CD19, (B) anti-CD4, and (C) anti-CD25,
and subsequent FACS analysis. Each dot on the scatter plot corresponds to one individual mouse.
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Figure 4. Effects of sub-cutaneous or intra-peritoneal treatment with ES-62 on the ex vivo response
of BDC2.5NOD splenocytes to BDC2.5 peptide. Four-week-old BDC2.5NOD mice were given two
injections of 2 µg ES-62 over the course of a week. After one week, splenocytes were harvested. Equal
numbers of splenocytes from each group were re-stimulated with 1 mg/mL BDC2.5 peptide. Culture
supernatants were harvested at 48 h and assessed for the presence of (A) IFN-γ, (B) IL-4, and (C) IL-10
by ELISA. Each dot on the scatter plot corresponds to the average cytokine secretion of splenocytes
from one individual mouse.
3.2. Multiple Sclerosis
EAE was induced in mice as described in Materials and Methods. ES-62 and SMAs 11a and 12b
were administered to C57BL/6 mice, but no effect was observed on EAE incidence or disease severity
(Figure 5A). Immunohistochemical staining with antibodies against CD4 and F4/80 on spinal cord
tissues was performed: there was a trend towards fewer infiltrating CD4+ cells when administering
SMAs (particularly 12b; Figure 5B) but no differences in F4/80+ cells (Figure 5C) in the spinal cord
between treatment groups. In addition, analysis of the IL-17 and IFN-γ levels in serum and in the
conditioned medium of MOG35–55-stimulated spleen and lymph node cells was undertaken, but there
were no significant differences in the levels of these two cytokines amongst any of the treatment groups
(results not shown).
3.3. Inflammatory Bowel Disease
To determine whether ES-62 or SMA 11a and 12b could attenuate inflammatory bowel-like disease,
chronic colonic inflammation was administered using four cycles of DSS in drinking water. ES-62, SMA
11a or 12b treatment could not prevent the weight loss observed in mice when their treatment started
on day 1 of DSS administration (Figure 6A). In fact, if anything, greater weight loss was observed in
ES-62-treated mice compared to PBS-treated mice. Additionally, no significant differences in colon
length, cellularity in LPMC, mesenteric lymph nodes (MLN), histology score, and cytokine secretion of
re-stimulated LPMC or MLN was observed between ES-62, SMA 11a or 12b, and PBS-treated mice
(Figure 6B–E and data not shown). To further characterise any protective effect of SMA 11a or 12b on
the development of colitis, a second model of chronic colitis, i.e., the adoptive T cell transfer model
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was used. Similar to the chronic DSS colitis model, there was no significant differences in weight loss,
colon length, cellularity in LPMC, MLN, histology score, and cytokine secretion of restimulated LPMC
or MLN between ES-62-, SMA 11a-, 12b- and PBS-treated mice (Figure 7 and data not shown).
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ Ȭ ȱ ȱ Ȭ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ Ȭ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱΐ ȱ Ȭ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ Ȭ ȱ ȱ ȱ
Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ
ȱ
ȱ ȱ ȱ ȱ Ȭ ȱ ȱ Ȭ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ Ȭ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱΐ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ· ȱ ȱ Ȭ ȱ ȱ ȱ Ȭ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ
ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȭ ȱ ȱ Ȭ·ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ Ȭ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
ȱ ȱ ȱ ȱ
ȱ
Figure 5. ES-62 and SMAs 11a and 12b do not prevent experimental autoimmune encephalomyelitis.
(A) Age 7–9 week-old mixed sex C57BL/6 mice were immunised with MOG35–55 peptide and treated
with PBS (control), ES-62, or SMAs 11a or 12b and clinical disease scores were monitored twice daily
(n = 5–7). There were no statistically significant differences amongst groups, and hence, SD values have
been omitted to ensure the clarity of the figure. Spinal cords were collected from treatment groups and
immunohistochemical analysis of CD4 (B) or F4/80 (C) was performed and representative images are
shown. Magnification = 20×.
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Figure 6. ES-62, and SMAs 11a and 12b do not prevent the induction of chronic colonic inflammation in
the DSS-colitis model. (A) Body weight changes (as percentage of the initial weight) from the initiation
of DSS-colitis was measured during four cycles of DSS with thrice weekly treatments of ES-62 or SMAs
(11a or 12b). (B) Colon length (cm) was measured at cull. (C) Total cell counts and the proportion of CD4+
T cells (D) present in the lamina propria mononuclear cells (LPMC) were measured. (E) Representative
Heamatoxylin and Eosin (H & E) staining of colons at time of sacrifice. Magnification = 100×. Data in
(A–D) represent the means± SD (n = 5) and statistical significance as determined by student’s t test (PBS
versus ES-62) is denoted by * p < 0.05.
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Figure 7. ES-62 SMAs do not attenuate T cell transfer colitis in mice. Naïve CD4+ T cells from wild
type (WT) mice were injected into Rag1−/− mice. PBS or SMAs (11a, 12b) were injected twice per week.
(A) Body weight changes as a percentage of the initial weight at day 1. (B) Colon length. (C) Total cell
counts in lamina propria mononuclear cells. (D) Representative H & E staining of colons at the time
of sacrifice. Magnification = 100×. For (A–C) data represent means ± SD. N = 5/group. * p < 0.05 as
determined by Student’s t-test for comparisons between PBS- and 12b-treated mice.
These data suggest that SMA 11a, and 12b are not efficient in preventing the development
of inflammation in two different models of chronic colitis with different underlying molecular
mechanisms of pathogenesis. While chronic DSS colitis depends on initial macrophage recognition of
commensal bacteria upon damage of the intestinal layer and subsequent T cell activation, the intestinal
inflammation in the adoptive T cell transfer model depends on the proliferation and differentiation of
effector T cells in recipient immunocompromised mice lacking Treg cells.
4. Discussion
The data presented in this manuscript indicate that ES-62 and its SMAs do not provide any
therapeutic benefits in models of T1D, MS and chronic IBD. This is despite the use of treatments
based on regimens that are successfully employed in other inflammatory disease models, which
apparently involve similar pathogenic mechanisms such as unresolving Th17-driven inflammation.
We could have undertaken further experiments employing additional doses of ES-62/SMAs, but our
previous experience with ovalbumin-induced airway hypersensitivity suggests that this would have
no significant effect on the results [9]. In attempting to understand these failures, the organ-specific
nature of the three resistant conditions, targeting pancreatic islets in the NOD mouse, CNS in EAE,
and colon in IBD, is a consideration. These organ-specific situations are quite different from the
autoimmune disease models (CIA; MRL/Lpr mouse) where ES-62/SMAs have previously shown
efficacy, in that the latter have a systemic disease component and exhibit various tissue co-morbidities,
reflecting the conditions found in their human disease counterparts. Thus, it is possible that ES-62 and
the SMAs might be more suited to tackling pathogenic cellular networks in disorders with a substantial
systemic inflammatory component [30,31]. However, at the same time, ES-62/SMAs are very effective
in models of asthma that, in being essentially a condition affecting the lungs, could be considered as
organ-specific in nature.
Thus, perhaps a more likely factor to consider is the induction of Treg responses, which dominate
host immunity involving helminth infections and can also be induced by a number of ES products.
Indeed, the induction of such cells by parasitic helminths or their ES products constitutes a protective
mechanism in the three ES-62-resistant disease models. For example, SEA-induced Tregs play a
role in preventing T1D in NODmice [15], H. polygrus-induced Tregs [32] represent one of the major
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mechanisms by which this worm is able to prevent colitis in mouse models [33] and infection of mice
with F. hepatica elicits a (modest) increase in FoxP3+ T cells in the pleural cavity, which is associated
with increased IL-10 and protection against EAE [19]. Of note therefore, although ES-62 promotes B
regulatory responses (Bregs) in models of each of asthma, RA and SLE, [3,5,34], it does not induce Treg
responses. Pertinent to this, although protective roles for Bregs have also been proposed for EAE/MS
and DSS colitis/IBD, these have generally reflected regulatory mechanisms involving their interaction
with Tregs [35]. Focusing on Bregs in particular, it is also worth pointing out that there is a lack of a
definitive Breg phenotype(s) and the precise mechanisms (IL-10-dependent and independent) and
phenotype of Bregs utilised appears to be disease-dependent. Indeed, as ES-62 appears to restore
different Breg subsets in the asthma, RA and SLE models [3,5,34], its potential inability to target the
Breg subtypes that are protective in EAE and DSS-colitis may provide a rationale for its failure to afford
protection in these models. Likewise, there is a single report of Breg protection against NOD-T1D,
the mechanism of which involves TGF-β-production and FasL-mediated apoptosis of auto-reactive T
cells [35], but perhaps reflecting the paucity of research in this area, B cell depletion studies in NOD
mice and T1D patients suggest that Bregs play a very minor, if any, role in preventing T1D [35]. In any
case, despite its ability to restore protective Bregs levels in some inflammatory conditions, its failure to
induce Treg-interacting Bregs and also as mentioned earlier, Tregs, may need to be taken into account
when considering ES-62’s failure to demonstrate protective effects against disease development in
certain models.
Given the role of the gut microbiome in regulating the homeostatic production of inflammation-
resolving Bregs in experimental arthritis [36], another potential reason underpinning ES-62-resistance
may relate to how the microbiome influences host (auto)immunity in specific conditions, and in
particular, the potentially differential impact of ES-62 and helminth infections in these diseases.
Certainly, perturbation of the gut microbiota has been shown to influence both ES-62-resistant
(diabetes [37], EAE [38] and IBD [39]) and -responsive (asthma [40,41], arthritis [42] and lupus [43])
inflammatory conditions in mice and humans. Perhaps pertinently, certain species of Clostridium can
promote Tregs, to regulate aberrant inflammation [44,45], and dietary supplementation with probiotics,
including Lactobacillus species, can reduce IBD and atopic dermatitis by inducing a strong FoxP3+CD4+
T regulatory response at the site of inflammation [46]. However, although the dramatic differences in
microbiota and inflammatory responses observed in animal facilities amongst labs and commercial
vendors [47] could contribute to the protective (or not) outcomes of ES-62 treatment in some of the
animal models tested, the differential effects of ES-62/SMAs on asthma and EAE were observed within
the same animal facility whilst the protective actions of ES-62 on CIA, MRL/Lpr mice, and both acute
and chronic asthma models were detected in a range of mouse strains housed in conventional and
SPF animal facilities in different geographical locations. Thus, any microbiome-related effects of ES-62
more likely reflect the differential changes in bacterial species in distinct intestinal microenvironments
induced under particular pathogenic conditions: for example, changes in the ileum and colon are
associated with Th17 and regulatory cell responses, respectively [36,48–50]. Thus, it seems likely that
analysis of the perturbation of the microbiota and its modulation by ES-62 in resistant and responsive
models might provide an important insight into the ability of ES-62 to ameliorate inflammatory
conditions, and the protective mechanisms involved.
Finally, it has recently become apparent that the primary effect of ES-62 and the SMAs on immune
system cells is to down-regulate the aberrantly elevatedMyD88-dependent responses pertaining during
chronic inflammation, restoring them back towards the steady-state levels observed in healthy animals.
This has been observed with macrophages [6], dendritic cells [51], mast cells [52], and Th17 cells [30],
and at least in the case of the SMAs, has been shown to reflect direct interaction with the MyD88 TIR
domain [53]. Interestingly, mice lacking MyD88 are resistant to the development of EAE [54] and this
may suggest that ES-62/SMAs’ mechanism of action involving reduction rather than the abrogation of
adaptor levels [6,30,51,52] may be insufficient to achieve protection against inflammatory responses
in this particular model. Alternatively, the reduced My88-dependent signalling in EAE-mice may
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be compensated for by other inflammatory pathways that are not activated in RA, SLE and asthma
models. Clearly, these are ideas that could be explored in future experiments.
In summary, ES-62 and its SMAs generally appear to be effective in treating diseases in model
systems that have a strong systemic inflammatory component rather than a more organ-specific
pathology. Thus, in the human situation, the SMAs are perhaps more likely to be better suited to
treating multifactorial disorders such as RA or SLE which have a range of co-morbidities. Finally,
although, ES-62 is somewhat unusual in not inducing Treg responses and this sets it apart to some
extent from other helminth-derived molecules, it also re-enforces that ES-62 is not simply a broad
immunosuppressant, but rather a focused immunomodulatory agent that can nevertheless treat a
variety of conditions.
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